Bioxcel therapeutics announces oral and poster presentations at the 2024 american society of clinical psychopharmacology (ascp) annual meeting

New haven, conn., may 21, 2024 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that rob risinger, m.d., chief medical officer of neuroscience, will deliver oral and poster presentations at the 2024 american society of clinical psychopharmacology (ascp) annual meeting. the meeting will take place may 28 to 31, 2024 in miami beach, fl.
BTAI Ratings Summary
BTAI Quant Ranking